MedTrace Logo

Intralesional Injections of Triamcinolone for Acne Vulgaris

NCT06170593 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-12-14

No results posted yet for this study

Summary

This proof-of-concept study seeks to investigate the safety of intralesional injections of triamcinolone for acne vulgaris lesions using an Intradermal Needle Adapter.

Conditions

  • Acne Vulgaris

Interventions

DRUG

Triamcinolone Injection

0.1mL of triamcinolone 1% solution per lesion

Sponsors & Collaborators

  • ACOM Labs

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2023-01-31
Completion
2023-02-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06170593 on ClinicalTrials.gov